Tianjin TEDA Biomedical Engineering Co. Ltd. Class H (8189) Stock Statistics & Valuation Metrics

Tianjin TEDA Biomedical Engineering Co. Ltd. Class H has a market cap or net worth of HK$554.94M. The enterprise value is HK$729.98.

Tianjin TEDA Biomedical Engineering Co. Ltd. Class H has 1,436,400,000 shares outstanding. The number of shares has decreased by -2.65% in one year.

Tianjin TEDA Biomedical Engineering Co. Ltd. Class H’s return on equity (ROE) is -7.23 and return on invested capital (ROIC) is -20.64%.

The current PE Ratio of Tianjin TEDA Biomedical Engineering Co. Ltd. Class H is ―. Tianjin TEDA Biomedical Engineering Co. Ltd. Class H’s PEG ratio is -0.04.

In the last 12 months, Tianjin TEDA Biomedical Engineering Co. Ltd. Class H had revenue of 509.43M and earned -88.47M in profits. Earnings per share was -0.04.

In the last 12 months, operating cash flow was -35.15M and capital expenditures -11.87M, giving a free cash flow of -47.02M billion.

Tianjin TEDA Biomedical Engineering Co. Ltd. Class H pays an annual dividend of ―, resulting in a dividend yield of ―

Tianjin TEDA Biomedical Engineering Co. Ltd. Class H upcoming earnings date is Apr 1, 2027, TBA (Not Confirmed).

Tianjin TEDA Biomedical Engineering Co. Ltd. Class H as a current ratio of 0.75, with Debt / Equity ratio of 897.73%

In the past 12 months, Tianjin TEDA Biomedical Engineering Co. Ltd. Class H has paid 593.33K in taxes.

Tianjin TEDA Biomedical Engineering Co. Ltd. Class H EV to EBITDA ratio is -45.41, with an EV/FCF ratio of -10.35.

Tianjin TEDA Biomedical Engineering Co. Ltd. Class H has HK$29.22M in cash and marketable securities with HK$109.79M in debt, giving a net cash position of -HK$80.56M billion.

Gross margin is 5.22%, with operating margin of -4.63%, and net profit margin of -17.37%.

The average price target for Tianjin TEDA Biomedical Engineering Co. Ltd. Class H is ―, which is 11.43% higher than the current price. The consensus rating is ―